三名安克森内部人士在2月18日出售了104,000美元的股票,股票价格在2月20日收盘时跌幅为6.5%-7.5%. Three Annexon insiders sold $104K in stock Feb 18, reducing stakes by 6.5%-7.5%, as shares closed at $4.90 on Feb 20.

2026年2月18日,CFO副总裁Ted Yednock和内幕人士Jamie Dananberg以每股5.10美元至5.11美元的价格共出售了20 000股股份,共筹集约104 000美元。 On February 18, 2026, three insiders at Annexon Inc.—executive vice president Ted Yednock, CFO, and insider Jamie Dananberg—sold a combined total of 20,000 shares at prices between $5.10 and $5.11 per share, collectively raising about $104,000. 此次出售减少了6.5%至7.5%，公司股价于2月20日收盘价为4.90美元，跌幅0.20美元，成交量低于平均水平。 The sales reduced their stakes by 6.5% to 7.5%, with the company’s stock closing at $4.90 on February 20, down $0.20, on below-average volume. Annexon是临床阶段生物技术开发补充疗法,针对神经退化和神经免疫疾病,其市场上限为5.8619亿美元,协商一致的“Moderate Buy”评级为17.00美元。 Annexon, a clinical-stage biotech developing complement-targeted therapies for neurodegenerative and neuroimmune diseases, has a market cap of $586.19 million and a consensus “Moderate Buy” rating with a $17.00 target. 其主要药物ANX005正在第二阶段对Guillain-Barré综合症和慢性神经退化状况进行试验。 Its lead drug, ANX005, is in Phase 2 trials for Guillain-Barré syndrome and chronic neurodegenerative conditions.